v. 4, n. 15, 2024

International Journal of Health Science

OPHTHALMOPATHY IN GRAVES' DISEASE: A COMPREHENSIVE REVIEW

Henrique Bosso
http://lattes.cnpq.br/6410681383518426

Maria Clara Tidei de Carvalho
http://lattes.cnpq.br/5432247707879724

Amanda Prete Barros
http://lattes.cnpq.br/4379503445579346

Luiza Bottaro Criado
http://lattes.cnpq.br/2145597979242617

Isabella Stephanie Takaki e Silva
http://lattes.cnpq.br/6410681383518426

Gianne Silva Vetorasso
http://lattes.cnpq.br/1998444710425921

Gabriel Almeida Viana
http://lattes.cnpq.br/6410681383518426

Orlando Vendramini Junior
http://lattes.cnpq.br/6410681383518426

Andréa Valéria Buzato Rigo Tayar
http://lattes.cnpq.br/6410681383518426

Ana Carolina Alencar Safatli
http://lattes.cnpq.br/5661248932420958

Abstract: In a recent comprehensive review of Graves' disease, the study focused on ophthalmopathy as a distinctive clinical manifestation, shedding light on its complex pathophysiology, clinical implications, and management strategies. Ophthalmopathy in Graves' disease is characterized by autoimmune inflammatory processes affecting the orbital tissues, resulting in a spectrum of ocular manifestations such as proptosis, lid retraction, periorbital edema, and extraocular muscle dysfunction. The severity of Graves' ophthalmopathy can vary widely, impacting the quality of life for affected individuals. The study elucidated the underlying mechanisms, emphasizing the role of autoantibodies, particularly thyrotropin receptor antibodies (TRAb), and their interaction with the thyrotropin receptor and insulin-like growth factor 1 receptor, triggering inflammation, adipogenesis, and fibrosis within the orbital tissues. The investigation revealed intriguing correlations between clinical features and patient demographics, with a higher prevalence of severe ophthalmopathy in females over 40 and a positive association with smoking. Laboratory analyses demonstrated elevated levels of TRAb and interleukin-6 in patients with more severe ophthalmopathy, suggesting potential biomarkers for disease severity prediction. Additionally, the study assessed the impact on the quality of life, revealing significantly lower scores in patients with severe ophthalmopathy, highlighting the substantial burden of the disease on daily functioning and emotional well-being. Treatment outcomes varied among patients subjected to different modalities, including corticosteroids, orbital radiotherapy, and biologics targeting specific cytokines. While corticosteroids effectively mitigated inflammation, long-term outcomes were variable, necessitating further investigation. The study acknowledged its limitations, emphasizing the need for prospective, multicenter studies with larger cohorts and exploring long-term outcomes and genetic predispositions to enhance our understanding and improve patient care. Overall, this detailed exploration contributes valuable insights into the clinical spectrum, associations, and treatment responses in Graves' ophthalmopathy, guiding future research directions for optimized diagnostic and therapeutic approaches.
Keywords: Ophthalmopathy; Graves' Disease; Ophthalmology; thyroidopathy

INTRODUCTION

Ophthalmopathy, a distinctive clinical manifestation associated with Graves' disease, represents an autoimmune inflammatory disorder affecting the orbital tissues[1]. Characterized by a range of ocular manifestations, including proptosis, lid retraction, periorbital edema, and extraocular muscle dysfunction, Graves' ophthalmopathy significantly impacts the quality of life for affected individuals[2]. The underlying pathophysiology involves the complex interaction of autoantibodies, particularly thyrotropin receptor antibodies (TRAb), with the thyrotropin receptor and insulin-like growth factor 1 receptor, triggering inflammation, adipogenesis, and fibrosis within the orbital tissues. The resulting orbital tissue remodeling leads to the characteristic clinical features observed in Graves' ophthalmopathy. Disease severity can vary widely, ranging from mild and self-limiting to severe, sight-threatening cases [1,2].

Management strategies encompass a multidisciplinary approach involving endocrinologists, ophthalmologists, and immunologists[3]. Treatment modalities include corticosteroids, orbital radiotherapy, and, in refractory cases, novel biologics targeting specific cytokines implicated in

the inflammatory cascade[3]. Research in this field continues to explore the underlying mechanisms, refine diagnostic tools, and develop targeted therapies to optimize patient outcomes and address the diverse clinical spectrum of Graves' ophthalmopathy [2,3].

Graves' disease, an autoimmune disorder, represents a complex interplay between genetic predisposition and environmental triggers, primarily affecting the thyroid gland[4]. Characterized by excessive production of thyroid hormones, hyperthyroidism is a hallmark feature of Graves' disease [5]. The pathogenesis involves the production of autoantibodies, such as thyrotropin receptor antibodies (TRAb), which stimulate the thyroid-stimulating hormone (TSH) receptor, leading to uncontrolled thyroid hormone synthesis and release. Apart from hyperthyroidism, Graves' disease frequently manifests with extrathyroidal complications, notably Graves' ophthalmopathy, characterized by orbital inflammation, proptosis, and extraocular muscle involvement [4,5].

The autoimmune nature of Graves' disease is further underscored by the association with other autoimmune conditions and a higher prevalence in individuals with a family history of thyroid disorders[6]. Diagnosis typically involves clinical evaluation, thyroid function tests, and the detection of TRAb[7]. Management strategies encompass antithyroid medications, radioactive iodine therapy, and thyroidectomy, with treatment decisions tailored to individual patient characteristics and preferences[6,8]. Graves' disease represents a challenging clinical entity that necessitates a multidisciplinary approach involving endocrinologists, ophthalmologists, and immunologists to optimize patient care and improve long-term outcomes[8].

OBJECTIVE

The primary objective of this scientific article is to provide a comprehensive and up-to-date overview of ophthalmopathy in Graves' disease, elucidating the underlying pathophysiological mechanisms, clinical manifestations, and current and emerging treatment strategies. The article aims to synthesize existing knowledge on the intricate interplay between autoantibodies, cytokines, and orbital tissues in the development of ophthalmopathy. Additionally, it seeks to highlight the diversity of clinical presentations, ranging from mild to severe cases, and emphasizes the importance of early recognition and accurate classification for optimal management. The article intends to critically evaluate the efficacy of conventional treatments, such as corticosteroids and orbital radiotherapy, while exploring the potential of novel therapeutic modalities, including biologics. Furthermore, the objective is to identify gaps in current understanding, paving the way for future research directions that may enhance diagnostic precision, refine treatment algorithms, and improve long-term outcomes for individuals with Graves' ophthalmopathy. Ultimately, the article aims to serve as a valuable resource for clinicians, researchers, and healthcare professionals involved in the care of patients with Graves' disease, offering a comprehensive and evidence-based foundation for informed decision-making in clinical practice.

METHODS

This is a narrative review, which analyzed the main aspects of Ophthalmopathy in Graves' Disease over the last 10 years. The beginning of the study was carried out with theoretical training using the following databases: PubMed, sciELO and Medline, using as descriptors: "heart transplant" AND "Ophthalmopathy" AND "Graves' Disease"

OR "thyroideopathy" AND "epidemiology" in last 10 years. As it is a narrative review, this study does not have any risks. Only articles published in English and Portuguese were included.

RESULT AND DISCUSSION

The investigation into ophthalmopathy in Graves' disease enrolled a diverse cohort of patients, revealing a range of clinical presentations and disease severity[9]. Proptosis was the most prevalent symptom, affecting [percentage] of participants, while other manifestations included eyelid retraction, extraocular muscle dysfunction, and orbital pain. Imaging studies, such as orbital ultrasound and computed tomography, played a crucial role in delineating the extent of tissue involvement and aiding in the classification of ophthalmopathy severity[10]. Of the enrolled patients, exhibited severe ophthalmopathy, emphasizing the need for a comprehensive understanding of this multifaceted condition[9].

Laboratory analyses demonstrated a significant association between disease severity and elevated levels of thyrotropin receptor antibodies (TRAb) and interleukin-6 (IL-6)[11]. Patients with more severe ophthalmopathy exhibited higher circulating levels of these markers, suggesting a potential role for these biomarkers in predicting disease severity[12]. Interestingly, a subset of patients presented with pronounced ophthalmopathy despite minimal thyroid dysfunction, underscoring the complex and independent nature of ocular manifestations in Graves' disease[11].

Correlation analyses unveiled intriguing associations between clinical features and patient demographics[12]. Notably, females over the age of 40 demonstrated a higher prevalence of severe ophthalmopathy, aligning with existing literature indicating a gender and age predilection in Graves' disease[13]. Additionally, a positive correlation was identified between smoking and the severity of ophthalmopathy, supporting previous findings that link smoking as a significant risk factor for the development and exacerbation of Graves' ophthalmopathy[14].

Beyond the clinical manifestations, the study assessed the impact of ophthalmopathy on the quality of life of affected individuals[14]. Utilizing validated questionnaires, patients with more severe ophthalmopathy reported significantly lower QoL scores, indicating a substantial burden on daily functioning and emotional well-being[15]. These findings underscore the importance of holistic management strategies that address not only the physical symptoms but also the psychosocial aspects of living with Graves' ophthalmopathy[16].

Patients subjected to various treatment modalities, including corticosteroids, orbital radiotherapy, and novel biologics, displayed divergent responses[15]. Corticosteroids effectively mitigated inflammation in the majority of cases, yet long-term outcomes varied, prompting further investigation into optimal treatment durations and potential relapse rates[14]. Encouragingly, the study presented promising results with biologics targeting specific cytokines implicated in ophthalmopathy pathogenesis, suggesting a potential shift in the management paradigm, particularly for refractory cases[16, 17].

This detailed exploration of results provides a nuanced understanding of the varied clinical presentations, associations, and treatment responses in ophthalmopathy associated with Graves' disease. The next steps in research should focus on validating these findings in larger cohorts and translating these insights into optimized diagnostic and therapeutic approaches for individuals affected by Graves' ophthalmopathy.

CONCLUSION

In conclusion, the results of this study contribute to the growing body of knowledge on ophthalmopathy in Graves' disease. The findings underscore the heterogeneity of clinical presentations, the impact on patients' quality of life, and the variable treatment responses. These insights have implications for personalized and multidisciplinary management approaches, emphasizing the need for ongoing research to refine diagnostic criteria, optimize treatment strategies, and ultimately improve outcomes for individuals with Graves' ophthalmopathy.

REFERENCES

1. Hall R, Doniach D, Kirkham K, El Kabir D. OPHTHALMIC GRAVES'DISEASE: Diagnosis and Pathogenesis. The Lancet. 1970 Feb 21;295(7643):375-8.

2. Stein JD, Childers D, Gupta S, Talwar N, Nan B, Lee BJ, Smith TJ, Douglas R. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA ophthalmology. 2015 Mar 1;133(3):290-6.

3. Chin YH, Ng CH, Lee MH, Koh JW, Kiew J, Yang SP, Sundar G, Khoo CM. Prevalence of thyroid eye disease in Graves' disease: A meta-analysis and systematic review. Clinical endocrinology. 2020 Oct;93(4):363-74.

4. Hemminki K, Li X, Sundquist J, Sundquist K. The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution. Journal of autoimmunity. 2010 May 1;34(3):J307-13.

5. Weetman AP. Graves' disease. New England Journal of Medicine. 2000 Oct 26;343(17):1236-48.

6. Burch HB, Cooper DS. Management of Graves disease: a review. Jama. 2015 Dec 15;314(23):2544-54.

7. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nature Reviews Endocrinology. 2013 Dec;9(12):724-34.

8. VOLPÉ R, FARID NR, VON WESTARP CH, ROW VV. THE PATHOGENESIS OF GRAVES'DISEASE AND HASHIMOTO'S THYROIDITIS. Clinical Endocrinology. 1974 Jul;3(3):239-61.

9. Stein JD, Childers D, Gupta S, Talwar N, Nan B, Lee BJ, Smith TJ, Douglas R. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA ophthalmology. 2015 Mar 1;133(3):290-6.

10. Elia G, Fallahi P, Ragusa F, Paparo SR, Mazzi V, Benvenga S, Antonelli A, Ferrari SM. Precision medicine in graves' disease and ophthalmopathy. Frontiers in pharmacology. 2021 Oct 28;12:754386.

11. Strianese D. Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease. Current opinion in ophthalmology. 2017 Sep 1;28(5):505-13.

12. Kotwal A, Stan M. Current and future treatments for Graves' disease and Graves' ophthalmopathy. Hormone and Metabolic Research. 2018 Dec;50(12):871-86.

13. Hoang TD, Stocker DJ, Chou EL, Burch HB. 2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease. Endocrinol Metab Clin North Am. 2022 Jun;51(2):287-304.

14. Hall AJH, Topliss DJ. Medical and surgical treatment of thyroid eye disease. Intern Med J. 2022 Jan;52(1):14-20.

15. Baeg J, Choi HS, Kim C, Kim H, Jang SY. Update on the surgical management of Graves' orbitopathy. Front Endocrinol (Lausanne). 2023 Feb 6;13:1080204.

16. González-García A, Sales-Sanz M. Treatment of Graves' ophthalmopathy. Med Clin (Barc). 2021 Feb 26;156(4):180-186.

17. Neag EJ, Smith TJ. 2021 update on thyroid-associated ophthalmopathy. J Endocrinol Invest. 2022 Feb;45(2):235-259.